Clinical Trial Update: Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating renal safety of adding everolimus to cyclosporine in heart transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• Everolimus (everolimus)
• cyclosporine microemulsion (cyclosporine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cardiac Transplantation | Phase 3 | Status: COMPLETED